PersoMed-I

Trial status: Closed

Last updated: 20 November, 2025

Protocol title

Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma (PersoMed-I)

Purpose of the study

PersoMed-I is phase II, randomised international trial of personalised therapy, including sonidegib, for adolescents and young adults with SHH pathway activated medulloblastoma.

Intervention

Sonidegib and radiotherapy

Study Chair

Co-Chairs: Professor David Ziegler and Associate Professor Liz Hovey

Coordinating Centre

NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: persomed.study@sydney.edu.au

Design

Multi-centre, international, randomized, open-label Phase II trial

Cancer Type

Medulloblastoma

Publications

DEVELOPMENT OF RANDOMIZED TRIALS IN ADULTS WITH MEDULLOBLASTOMA—THE EXAMPLE OF EORTC 1634-BTG/NOA-23. Peter Hau, Didier Frappaz, Elizabeth Hovey, Martin G. McCabe, Kristian W. Pajtler, Benedikt Wiestler, Clemens Seidel, Stephanie E. Combs, Linda Dirven, Martin Klein, Antoinette Anazodo, Elke Hattingen, Silvia Hofer, Stefan M. Pfister, Claus Zimmer, Rolf-Dieter Kortmann, Marie-Pierre Sunyach, Ronan Tanguy, Rachel Effeney, Andreas von Deimling, Felix Sahm, Stefan Rutkowski, Anna S. Berghoff, Enrico Franceschi, Estela Pineda, Dagmar Beier, Ellen Peeters, Thierry Gorlia, Maureen Vanlancker, Jacoline E. C. Bromberg, Julien Gautier, David S. Ziegler, Matthias Preusser, Wolfgang Wick and Michael Weller. Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. Cancers. 13(14), 3451 (2021). Published online 9 July 2021. Article available on https://doi.org/10.3390/cancers13143451

Trials & Research